CAS 14271-05-7

Dihydro-α-ergocryptine mesylate

Description:

Dihydro-α-ergocryptine mesylate is a semi-synthetic derivative of ergot alkaloids, primarily used for its pharmacological properties. It is characterized by its ability to act as a dopamine receptor agonist, which makes it relevant in the treatment of conditions such as Parkinson's disease and other movement disorders. The substance typically appears as a white to off-white crystalline powder and is soluble in organic solvents, with limited solubility in water. Its chemical structure includes a complex tetracyclic ring system, which is common among ergot derivatives, contributing to its biological activity. Dihydro-α-ergocryptine mesylate is often administered in the form of its mesylate salt, enhancing its stability and bioavailability. As with many pharmacologically active compounds, it may exhibit side effects, and its use should be monitored in clinical settings. Proper handling and storage conditions are essential to maintain its efficacy and safety profile.

Formula: C₃₂H₄₃N₅O₅·CH₄O₃S

InChI: InChI=1S/C32H43N5O5.CH4O3S/c1-17(2)12-25-29(39)36-11-7-10-26(36)32(41)37(25)30(40)31(42-32,18(3)4)34-28(38)20-13-22-21-8-6-9-23-27(21)19(15-33-23)14-24(22)35(5)16-20;1-5(2,3)4/h6,8-9,15,17-18,20,22,24-26,33,41H,7,10-14,16H2,1-5H3,(H,34,38);1H3,(H,2,3,4)/t20-,22-,24-,25+,26+,31-,32+;/m1./s1

InChI key: InChIKey=TZGKQIBPZOZAKF-PJLVGBPESA-N

SMILES: O[C@@]12N([C@@H](CC(C)C)C(=O)N3[C@]1(CCC3)[H])C(=O)[C@@](NC(=O)[C@@H]4C[C@@]5(C=6C=7C(C[C@]5(N(C)C4)[H])=CNC7C=CC6)[H])([C@@H](C)C)O2.S(C)(=O)(=O)O

Synonyms:

• (5'Alpha,10Alpha)-12'-Hydroxy-5'-(2-Methylpropyl)-3',6',18-Trioxo-2'-(Propan-2-Yl)-9,10-Dihydroergotaman Methanesulfonate (1:1)
• 8H-Oxazolo[3,2-a]pyrrolo[2,1-c]pyrazine, ergotaman-3′,6′,18-trione deriv.
• 9,10-Dihydroergocryptine methanesulfonate
• 9,10alpha-Dihydro-12'-hydroxy-5'alpha-isobutyl-2'-isopropylergotaman-3',6',18-trione monomethanesulphonate
• Ccris 6730
• Cripar
• Dihydro-alpha-ergocryptine mesylate
• Dihydro-α-ergocryptine mesylate
• Ergocryptine, dihydro-, methanesulfonate
• Ergotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'alpha,10alpha)-, monomethanesulfonate (salt)
• Ergotaman-3′,6′,18-trione, 9,10-dihydro-12′-hydroxy-2′-(1-methylethyl)-5′-(2-methylpropyl)-, (5α,10α)-, methanesulfonate (1:1)
• Ergotaman-3′,6′,18-trione, 9,10-dihydro-12′-hydroxy-2′-(1-methylethyl)-5′-(2-methylpropyl)-, (5′α,10α)-, monomethanesulfonate (salt)
• Indolo[4,3-fg]quinoline, ergotaman-3′,6′,18-trione deriv.
• Unii-Z4I7Bu58Dn
• alpha-Dihydroergocryptine

Dihydro-α-ergocryptine mesylate

CAS: 14271-05-7

Dihydro-alpha-ergocryptine mesylate is a drug that inhibits the effects of ergotamine and other drugs. It is used in animals to treat drug reactions, such as those caused by morphine and penicillin. Dihydro-alpha-ergocryptine mesylate can be detected in urine samples for up to 72 hours after administration. The pharmacokinetic properties of this drug are not well understood, but there is a linear relationship between dose and plasma concentration. The clinical response to dihydro-alpha-ergocryptine mesylate has been shown to be dose dependent. This drug also has dopaminergic properties, which may be due to its ability to bind with dopamine receptors in the central nervous system. There are several symptoms that may be related to taking this drug, including drowsiness or fatigue, nausea or vomiting, dry mouth, muscle spasms, and involuntary shaking of a part of the body (tremor).

Formula: C₃₃H₄₇N₅O₈S

Purity: Min. 95%

Molecular weight: 673.82 g/mol

Ref: 3D-FD176343